AR044152A1 - Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad - Google Patents
Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidadInfo
- Publication number
- AR044152A1 AR044152A1 ARP040101491A ARP040101491A AR044152A1 AR 044152 A1 AR044152 A1 AR 044152A1 AR P040101491 A ARP040101491 A AR P040101491A AR P040101491 A ARP040101491 A AR P040101491A AR 044152 A1 AR044152 A1 AR 044152A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- halo
- formula
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- -1 1-piperidinylcarbonyl Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/58—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente se refiere a ciertos compuestos de ácido alquilarílico, composiciones, y métodos para tratar o prevenir la obesidad y enfermedades relacionadas. Reivindicación 1: Un compuesto de fórmula (1) en el cual Q es O, S o NR5; A es una ligadura seleccionada del resto de fórmula (2) en la cual p es 1 o 2 y el resto de fórmula (3) en la cual m es 0 y n es 1, 2, 3 o 4, o m es 1 y n es 1, 2, o 3 y en el cual dicha ligadura está sustituida en forma opcional por uno o dos grupos R8; R1 y R2 se seleccionan en forma independiente de H, halo, alquilo C1-6, y alcoxi C1-6; R3 se selecciona de H, alquilo C1-6 sustituido en forma opcional por hidroxi, y fenilo sustituido en forma opcional con alquilo C1-6, alcoxi C1-6 o halo; R4 se selecciona de H, nitro, y alquilo C1-6; o R3 y R4 pueden, cuando se los toma junto con los átomos de C a los cuales están unidos, formar un anillo de benceno sustituido en forma opcional con hasta dos sustituyentes seleccionados de halo, alquilo C1-6, alcoxi C1-6,,nitro, ciano, haloalquilo C1-6, haloalcoxi C1-6, aminocarbonilo, alquilo (C1-6)aminocarbonilo, bis[alquilo (C1-6)]aminocarbonilo, aminosulfonilo, alquil(C1-6)aminosulfonilo, bis[alquilo(C1-6)]aminosulfonilo, C1-6alquilcarbonilamino. alquil(C1-6)sulfonilamino, hidroxi-alquil (C2-6)aminocarbonilo, 1-morfolinilcarbonilo, 1-piperidinilcarbonilo, y cuando dos de dichos sustituyentes del anillo de benceno son alquilo C1-6 y están unidos a átomos de C adyacentes del anillo de benceno, pueden unirse para formar un anillo carbocíclico de 5-7 miembros; R5 es H o alquilo C1-6; R6 es H; R7 es H o alquilo C1-6 sustituido en forma opcional con alcoxi C1-6, bis[alquil(C1-3)]amino o fenilo sustituido en forma opcional con halo, alquilo C1-6, alcoxi C1-6, o ciano; o R6 y R7 son ambos alquilo C1-6; o R6 y R7 pueden formar, junto con el átomo de C al cual están unidos, un anillo carbocíclico de 3 a 5 miembros, o un anillo de 6 miembros representado por el resto de fórmula (4) en el cual W es CH2, C(CH3)2, O, NR9, S, o SO2; R8 es alquilo C1-6; y R9 es H o alquilo C1-6; o sus sales y ésteres aceptables desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46961903P | 2003-05-09 | 2003-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044152A1 true AR044152A1 (es) | 2005-08-24 |
Family
ID=33452304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101491A AR044152A1 (es) | 2003-05-09 | 2004-04-30 | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US7091228B2 (es) |
| EP (1) | EP1633722B1 (es) |
| JP (1) | JP4759517B2 (es) |
| KR (1) | KR20060009916A (es) |
| CN (1) | CN1816531A (es) |
| AR (1) | AR044152A1 (es) |
| AT (1) | ATE518841T1 (es) |
| AU (1) | AU2004238258A1 (es) |
| BR (1) | BRPI0410170A (es) |
| CA (1) | CA2524470A1 (es) |
| CL (1) | CL2004000969A1 (es) |
| EC (1) | ECSP056210A (es) |
| ES (1) | ES2369220T3 (es) |
| GT (1) | GT200400092A (es) |
| MA (1) | MA27843A1 (es) |
| MX (1) | MXPA05012061A (es) |
| NO (1) | NO20055832L (es) |
| NZ (1) | NZ543993A (es) |
| PE (1) | PE20050265A1 (es) |
| RU (1) | RU2357959C2 (es) |
| TW (1) | TW200510334A (es) |
| UY (1) | UY28314A1 (es) |
| WO (1) | WO2004100881A2 (es) |
| ZA (1) | ZA200509883B (es) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006044775A2 (en) * | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
| BRPI0519058A2 (pt) | 2004-12-14 | 2008-12-23 | Astrazeneca Ab | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto |
| WO2006082952A1 (ja) * | 2005-02-01 | 2006-08-10 | Takeda Pharmaceutical Company Limited | アミド化合物 |
| AU2006210056A1 (en) * | 2005-02-07 | 2006-08-10 | F. Hoffmann-La Roche Ag | Inhibitors of diacylglycerol acyltransferase (DGAT) |
| WO2006113919A2 (en) * | 2005-04-19 | 2006-10-26 | Bayer Pharmaceuticals Corporation | Aryl alkyl acid derivatives for and use thereof |
| AU2006258917A1 (en) * | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as DGAT inhibitors |
| CA2617055A1 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity |
| US8097610B2 (en) * | 2005-08-26 | 2012-01-17 | Shionogi & Co., Ltd. | Derivative having PPAR agonistic activity |
| KR20080063865A (ko) | 2005-11-28 | 2008-07-07 | 에프. 호프만-라 로슈 아게 | 다이아실글리세롤 아실전이효소(ｄｇａｔ)의 저해제 |
| WO2007071966A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors |
| EP2418202B1 (en) * | 2006-03-31 | 2014-01-29 | Novartis AG | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors |
| US20080293785A1 (en) * | 2006-04-11 | 2008-11-27 | Connolly Peter J | Substituted benzothiazole kinase inhibitors |
| WO2007123949A2 (en) * | 2006-04-21 | 2007-11-01 | Schering Corporation | Cannabinoid receptor modulators |
| WO2007137103A2 (en) * | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| US20080064717A1 (en) * | 2006-05-19 | 2008-03-13 | Rajesh Iyengar | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| CN101460470B (zh) * | 2006-05-30 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | 作为dgat1抑制剂的1,3,4-二唑衍生物 |
| MX2008015228A (es) * | 2006-05-30 | 2008-12-12 | Astrazeneca Ab | Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a. |
| WO2007141502A1 (en) * | 2006-06-06 | 2007-12-13 | Astrazeneca Ab | Chemical compounds |
| WO2007141517A1 (en) * | 2006-06-08 | 2007-12-13 | Astrazeneca Ab | Benzimidazoles and their use for the treatemnt of diabetes |
| GB0611506D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611552D0 (en) * | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| WO2008047694A1 (fr) * | 2006-10-13 | 2008-04-24 | Aska Pharmaceutical Co., Ltd. | Procédé de fabrication d'un composé benzothiazole |
| CN101636155A (zh) | 2006-11-29 | 2010-01-27 | 艾博特公司 | 二酰甘油o-酰基转移酶1型酶的抑制剂 |
| AU2008236616A1 (en) * | 2007-04-09 | 2008-10-16 | Scidose, Llc | Combinations of statins and anti-obesity agent |
| NZ580660A (en) | 2007-04-30 | 2012-02-24 | Abbott Lab | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| KR20100019470A (ko) * | 2007-04-30 | 2010-02-18 | 아보트 러보러터리즈 | 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 １ 효소의 억제제 |
| EP2152271B1 (en) | 2007-06-08 | 2015-10-21 | Janssen Pharmaceutica, N.V. | Piperidine/piperazine derivatives |
| ES2536406T3 (es) | 2007-06-08 | 2015-05-25 | Janssen Pharmaceutica, N.V. | Derivados de piperidina/piperazina |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| JP5464709B2 (ja) * | 2007-06-08 | 2014-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペリジン／ピペラジン誘導体 |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| NZ586104A (en) | 2007-12-20 | 2012-02-24 | Astrazeneca Ab | Carbamoyl compounds as dgat1 inhibitors 190 |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8394823B2 (en) * | 2008-04-11 | 2013-03-12 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as DGAT1 inhibitors |
| US8324241B2 (en) * | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
| PE20100083A1 (es) * | 2008-06-05 | 2010-02-17 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| EP3025727A1 (en) * | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| US20110319396A1 (en) * | 2009-01-23 | 2011-12-29 | Msd K.K. | Benzodiazepin-2-on derivatives |
| WO2010107768A1 (en) | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| TW201103895A (en) | 2009-06-19 | 2011-02-01 | Astrazeneca Ab | Chemical compounds |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| EP2477498A4 (en) | 2009-09-14 | 2013-02-27 | Merck Sharp & Dohme | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE |
| NZ599855A (en) | 2009-11-05 | 2014-06-27 | Piramal Entpr Ltd | Carboxy oxazole or thiazole compounds as dgat - 1 inhibitors useful for the treatment of obesity |
| AU2011215870B2 (en) * | 2010-02-09 | 2016-01-28 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| NZ602125A (en) | 2010-03-30 | 2014-01-31 | Novartis Ag | Uses of dgat1 inhibitors |
| WO2012064569A1 (en) * | 2010-11-08 | 2012-05-18 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
| HUE029002T2 (en) * | 2010-12-17 | 2017-01-30 | Mitsubishi Tanabe Pharma Corp | Continuous aricyclic compounds |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN102757420B (zh) * | 2011-04-28 | 2015-02-04 | 中国科学院上海药物研究所 | 联杂芳基羧酸类化合物、其制备方法,包含该化合物的药物组合物、及用途 |
| KR20130013199A (ko) | 2011-07-27 | 2013-02-06 | 한미약품 주식회사 | 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| TW201317229A (zh) * | 2011-09-14 | 2013-05-01 | Daiichi Sankyo Co Ltd | 稠合雜環衍生物 |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013056679A1 (en) * | 2011-10-21 | 2013-04-25 | Beijing Hanmi Pharmaceutical Co., Ltd | Novel heteroaryl-amino derivatives |
| EA201400990A1 (ru) | 2012-04-06 | 2015-01-30 | Пфайзер Инк. | Ингибиторы диацилглицеринацилтрансферазы 2 |
| JP5977349B2 (ja) | 2012-06-15 | 2016-08-24 | 田辺三菱製薬株式会社 | 芳香族複素環化合物 |
| JP5721032B2 (ja) * | 2012-06-15 | 2015-05-20 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| LT3119757T (lt) | 2014-03-17 | 2018-07-10 | Pfizer Inc. | Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme |
| MX375720B (es) * | 2016-09-09 | 2025-03-04 | Hoffmann La Roche | Proceso para preparacion de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-beta;3',4'-d]pirrol. |
| EP3305786A3 (de) | 2018-01-22 | 2018-07-25 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| EA202092190A1 (ru) | 2018-03-16 | 2020-11-19 | Анджи Фармасьютикалз Инк. | Композиции и способы для лечения сильного запора |
| AU2019318209B2 (en) | 2018-08-10 | 2025-09-25 | Diapin Therapeutics, Llc | Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders |
| WO2021066608A1 (ko) * | 2019-10-02 | 2021-04-08 | 주식회사 클로소사이언스 | 항노화 유전자 klotho의 발현을 유도하는 화합물 및 이의 용도 |
| ES3016132T3 (en) * | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| WO2023085931A1 (en) | 2021-11-11 | 2023-05-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Hepatic organoids |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2112840A1 (de) | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-buttersaeuren,ihre Salze und Ester |
| NL264710A (es) * | 1960-05-13 | |||
| US3299087A (en) * | 1961-04-24 | 1967-01-17 | Geigy Chem Corp | Nu, nu'-bis-(thiazolyl)-phenylenediamines |
| DE2112716A1 (de) | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester |
| US3997589A (en) | 1971-03-17 | 1976-12-14 | Boehringer Ingelheim Gmbh | 4-(2'-Fluoro-4-biphenylylr-4-oxo-butyric acid and esters and salts thereof |
| DE2112715A1 (de) | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-4-hydroxybuttersaeuren,ihre Salze,Ester und Lactone |
| US4021479A (en) | 1971-03-17 | 1977-05-03 | Boehringer Ingelheim Gmbh | Derivatives of 4-(4-biphenylyl)-butyric acid |
| DE3825617C2 (de) | 1988-07-28 | 1993-11-18 | W D Schumacher | Einrichtung zur Entfernung von Schmutz oder anderen Verunreinigungen |
| US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
| US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
| RU2109736C1 (ru) * | 1992-12-17 | 1998-04-27 | Санкио Компани Лимитед | Производные бифенила и способ их получения |
| GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
| GB2276161A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benzanilide derivatives |
| GB2276162A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benazilide derivatives |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| US5886022A (en) * | 1995-06-05 | 1999-03-23 | Bayer Corporation | Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors |
| TW429256B (en) * | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
| ATE406448T1 (de) | 1998-06-24 | 2008-09-15 | David Gladstone Inst | Diacylglycerin o-acyltransferase |
| US6344548B1 (en) | 1998-06-24 | 2002-02-05 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| JP4514952B2 (ja) | 1998-07-02 | 2010-07-28 | カルジーン エルエルシー | ジアシルグリセロールアシルトランスフェラーゼタンパク質 |
| US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
| EP1031349A1 (en) | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| MXPA01012317A (es) | 2000-12-28 | 2002-07-22 | Warner Lambert Co | Prueba de aciltransferasa del diacilglicerol (dgat). |
-
2004
- 2004-04-30 AR ARP040101491A patent/AR044152A1/es unknown
- 2004-05-06 BR BRPI0410170-7A patent/BRPI0410170A/pt not_active IP Right Cessation
- 2004-05-06 AU AU2004238258A patent/AU2004238258A1/en not_active Abandoned
- 2004-05-06 CL CL200400969A patent/CL2004000969A1/es unknown
- 2004-05-06 AT AT04751430T patent/ATE518841T1/de not_active IP Right Cessation
- 2004-05-06 JP JP2006532796A patent/JP4759517B2/ja not_active Expired - Fee Related
- 2004-05-06 MX MXPA05012061A patent/MXPA05012061A/es unknown
- 2004-05-06 ES ES04751430T patent/ES2369220T3/es not_active Expired - Lifetime
- 2004-05-06 WO PCT/US2004/014036 patent/WO2004100881A2/en not_active Ceased
- 2004-05-06 CA CA002524470A patent/CA2524470A1/en not_active Abandoned
- 2004-05-06 KR KR1020057021232A patent/KR20060009916A/ko not_active Ceased
- 2004-05-06 CN CNA2004800191925A patent/CN1816531A/zh active Pending
- 2004-05-06 EP EP04751430A patent/EP1633722B1/en not_active Expired - Lifetime
- 2004-05-06 NZ NZ543993A patent/NZ543993A/en unknown
- 2004-05-06 US US10/839,833 patent/US7091228B2/en not_active Expired - Fee Related
- 2004-05-06 RU RU2005138134/04A patent/RU2357959C2/ru not_active IP Right Cessation
- 2004-05-07 UY UY28314A patent/UY28314A1/es not_active Application Discontinuation
- 2004-05-07 TW TW093112839A patent/TW200510334A/zh unknown
- 2004-05-07 PE PE2004000471A patent/PE20050265A1/es not_active Application Discontinuation
- 2004-05-07 GT GT200400092A patent/GT200400092A/es unknown
-
2005
- 2005-11-24 MA MA28625A patent/MA27843A1/fr unknown
- 2005-12-06 ZA ZA200509883A patent/ZA200509883B/en unknown
- 2005-12-08 NO NO20055832A patent/NO20055832L/no not_active Application Discontinuation
- 2005-12-09 EC EC2005006210A patent/ECSP056210A/es unknown
-
2006
- 2006-01-27 US US11/341,197 patent/US7423156B2/en not_active Expired - Fee Related
-
2008
- 2008-08-04 US US12/185,813 patent/US20090197795A1/en not_active Abandoned
- 2008-09-05 US US12/231,878 patent/US8013166B2/en not_active Expired - Fee Related
- 2008-09-08 US US12/206,721 patent/US7968576B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| AR043049A1 (es) | Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR050540A1 (es) | Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide | |
| BRPI0810929B8 (pt) | uso de um composto de fórmula 1 | |
| AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR038834A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| CO6140059A2 (es) | Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3) | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| AR039665A1 (es) | Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| AR064389A1 (es) | Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. | |
| AR059516A1 (es) | Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas | |
| AR046778A1 (es) | Compuestos heterociclicos de acido boronico. metodos de obtencion y composiciones farmaceuticas. | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| BRPI0907122B8 (pt) | compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos | |
| CR10034A (es) | Derivados de oxadiazol | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| EA201071019A1 (ru) | Кристаллические формы производных фениламинопиримидина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |